-
Product Insights
Thyroid Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Thyroid Cancer - Drugs In Development, 2023’, provides an overview of the Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Uveal Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Uveal Melanoma - Drugs In Development, 2023’, provides an overview of the Uveal Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Uveal Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Bone Marrow Transplant Rejection – Drugs In Development, 2023
Global Markets Direct’s, ‘Bone Marrow Transplant Rejection - Drugs In Development, 2023’, provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Gallbladder Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Gallbladder Cancer - Drugs In Development, 2023’, provides an overview of the Gallbladder Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gallbladder Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Community Acquired Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community Acquired Pneumonia - Drugs In Development, 2023’, provides an overview of the Community Acquired Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community Acquired Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexmarilimab in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexmarilimab in Refractory Acute Myeloid Leukemia Drug Details: Bexmarilimab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexmarilimab in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexmarilimab in Relapsed Acute Myeloid Leukemia Drug Details: Bexmarilimab is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexmarilimab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexmarilimab in Gastric Cancer Drug Details: Bexmarilimab is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bexmarilimab in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bexmarilimab in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bexmarilimab in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Bexmarilimab is...